title: Juicing Tregs in situ to improve kidney allograft outcomes.
abstract: Targeted deletion of the sirtuin-1, Sirt-1, gene in mouse T cells results in enhanced CD4(+) T regulatory cell function. When these mice are used as kidney allograft recipients, this deletion confers marked improvements in allograft function and survival with the development of donor-specific nonresponsiveness. Similar kidney allograft outcomes are produced in wild-type recipients treated with pharmacologic Sirt-1 inhibitors. These studies suggest a novel strategy for enhancing the immunosuppressive function of Tregs to improve graft outcomes in kidney transplant patients.
authors.affiliation: Department of Immunology and the Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: fairchr@ccf.org.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Fairchild
mesh_terms: D064591:Allografts; D000818:Animals; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation; D050378:T-Lymphocytes, Regulatory
chemical_list: D007166:Immunosuppressive Agents